

HER2+ Cancer



Identifying actionable biomarkers may transform cancer care and improve patient outcomes^{1,2}


- HER2+ cancer is characterized by the overexpression of the HER2 protein, a tyrosine kinase receptor growth-promoting protein expressed on the surface of various tissue cells^{3,4}
- Various HER2+ cancers may be associated with a more aggressive tumor, poor prognosis, and shorter survival upon diagnosis³⁻⁶
- Historically, the focus of HER2 biomarker testing and targeted treatments has been in breast and gastric cancer,^{7,8} but NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have increasingly recommended HER2 testing in multiple solid tumors, outside of just breast and gastric⁹⁻¹⁸
- With a rise in treatments for HER2+ in many solid tumors, integrating routine, actionable HER2 screening across tumor types may be pivotal in improving patient outcomes^{1,19}

The deciphEHR™ program provides educational resources on biomarker characteristics and best practices to help healthcare providers, health systems, hospitals, and specialty practices leverage their electronic health record (EHR) systems to triage suspect patients for further clinician evaluation, leading to rapid, accurate biomarker testing.



HER2 positivity has been found across solid tumors

The following are approximate prevalence rates of HER2+ cancer, defined as a score of 2+/3+ on an immunohistochemistry (IHC) test, outside of breast and gastric*:



NCCN Guidelines® recommend HER2 testing in multiple solid tumors.^{9-18†}



In partnership with Alexion

*Because HER2 testing has not yet been fully integrated into standard practice for many solid tumor types, it is possible that HER2+ has a higher prevalence than currently reported.⁴⁶ Variability in reporting of HER2 overexpression may stem in part from significant variation in the HER2 testing methods, interpretation and scoring criteria used.³⁸

†See the NCCN Guidelines® for detailed recommendations.

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.



There is a cost to delaying or missing a HER2+ diagnosis...



Patients with missed HER2+ diagnoses have a loss of quality-adjusted life-years and face a higher risk of disease recurrence⁴⁷



In one study, the loss of quality-adjusted life-years in patients due to missed HER2+ diagnoses led to an estimated \$1 billion economic societal loss⁴⁷




Biomarker-driven, personalized medicine has been found to generate cost savings for healthcare organizations by decreasing costs associated with drug waste, hospital resource utilization, and side-effect management⁴⁸

...but effective biomarker testing in the right populations, at the right time, can help

- ✓ The data your organization may need to more rapidly identify patients for HER2 testing may exist in your electronic health record (EHR) system
- ✓ Properly identifying patients may help guide personalized, targeted treatments for better patient outcomes¹



Leveraging electronic health record (EHR) data may help healthcare organizations rapidly triage patients for further clinical evaluation for biomarker testing⁴⁹





AstraZeneca provides educational resources to help you leverage your EHR, which may help increase frequency of HER2 biomarker testing across tumor types

- Ineffective or delayed treatment may have devastating effects, as HER2+ is associated with aggressive disease and poor prognosis in various tumor types³⁻⁶
- With a rise in HER2-targeted therapies, integrating routine HER2 screening across tumor types will be pivotal in improving patient outcomes^{1,19}
- The data needed to correctly and rapidly diagnose patients may exist in your EHR
- With the assistance of the deciphEHR™ program's educational resources and biomarker best practices, physicians can triage patients for HER IHC biomarker testing, agnostic of tumor type, and provide targeted, effective therapies more rapidly

Visit deciphEHRoncology.com or contact your AstraZeneca representative to find out how utilizing your EHR system can help you triage patients who would benefit from further clinical evaluation for HER2+ cancer.



| In partnership with Alexion





References

1. Moore DC, Guinigundo AS. The role of biomarkers in guiding clinical decision-making in oncology. *J Adv Pract Oncol*. 2023;14(Suppl 1):15-37. 2. Albagoush SA, Zubair M, Limaïem F. Tissue Evaluation for HER2 Tumor Marker. *StatPearls*. 2024. 3. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. *Mol Biol Int*. 2014;2014(1):852748. 4. Gutierrez C, Schiff R. HER2: Biology, detection, and clinical implications. *Arch Pathol Lab Med*. 2011;135(1):55-62. 5. English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: Therapeutic implications for gynecologic malignancies. *Mol Diagn Ther*. 2013;17:85-99. 6. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis. *Cancer*. 2005;103(9):1865-1873. 7. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline focused update. *J Clin Oncol*. 2018;36(20):2105-2122. 8. Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. *J Clin Oncol*. 2017;35(4):446-464. 9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancers V.6.2024. 10. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V.6.2024. 11. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer V.1.2025. 12. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Uterine Neoplasms V.1.2025. 13. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.1.2025. 14. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2025. 15. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer V.3.2024. 16. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.6.2024. 17. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Head and Neck Cancers V.2.2025. 18. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Vaginal Cancer V.3.2025. 19. Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: A systematic review. *Biomark Res*. 2024;12(1):16. 20. Egebjerg K, Harwood CD, Woller NC, Kristensen CA, Mau-Sørensen M. HER2 positivity in histological subtypes of salivary gland carcinoma: A systematic review and meta-analysis. *Front Oncol*. 2021;11:693394. 21. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: Dependence on histological subtype. *Clin Cancer Res*. 2004;10(3):944-946. 22. Uzunparmak B, Haymaker C, Raso G, et al. HER2-low expression in patients with advanced or metastatic solid tumors. *Ann Oncol*. 2023;34(11):1035-1046. 23. Heinmöller P, Gross C, Beyser K, et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. *Clin Cancer Res*. 2003;9(14):5238-5243. 24. Zinner RG, Glisson BS, Fossella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: Report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. *Lung Cancer*. 2004;44(1):99-110. 25. Takenaka M, Hanagiri T, Shinohara S, et al. The prognostic significance of HER2 overexpression in non-small cell lung cancer. *Anticancer Res*. 2011;31(12):4631-4636. 26. Vivaldi C, Fornaro L, Ugolini C, et al. HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer. *Oncologist*. 2020;25(10):886-893. 27. Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javie M. Overexpression of the HER2/neu gene: A new therapeutic possibility for patients with advanced gallbladder cancer. *Gastrointest Cancer Res*. 2014;7(2):42-48. 28. Chou A, Waddell N, Cowley MJ, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. *Genome Med*. 2013;5(8):78. 29. Han SH, Ryu KH, Kwon AY. The prognostic impact of HER2 genetic and protein expression in pancreatic carcinoma—HER2 protein and gene in pancreatic cancer. *Diagnostics (Basel)*. 2021;11(4):653. 30. Heppner IB, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. *Br J Cancer*. 2014;111(10):1977-1984. 31. Wang XY, Zheng ZX, Sun Y, et al. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. *World J Gastrointest Oncol*. 2019;11(4):335-347. 32. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. *Eur Urol*. 2011;60(2):350-357. 33. Gårdmark T, Wester K, De La Torre M, Carlsson J, Malmström PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. *BJU Int*. 2005;95(7):982-986. 34. Moustakas G, Kampantais S, Nikolaidou A, Vakalopoulos I, Tzioufa V, Dimitriadis G. HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy. *J Int Med Res*. 2020;48(1):300060519895847. 35. Moktefi A, Pouessel D, Liu J, et al. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. *Mod Pathol*. 2018;31(8):1270-1281. 36. Semiz HS, Pala EE, Can B, Atag E, Gungor H, Sancı M. cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma. *Türk Patoloji Derg*. 2023;39(1):55-63. 37. Vermij L, Singh N, Leon-Castillo A, et al. Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. *Histopathology*. 2021;79(4):533-543. 38. Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. *Mod Pathol*. 2013;26(12):1605-1612. 39. Halle MK, Tangen IL, Berg HF, et al. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. *Br J Cancer*. 2018;118(3):378-387. 40. Tuefferd M, Couturier J, Penault-Llorca F, et al. HER2 status in ovarian carcinomas: A multicenter GINECO study of 320 patients. *PLoS One*. 2007;2(11):e1138. 41. Chung YW, Kim S, Hong JH, et al. Overexpression of HER2/HER3 and clinical feature of ovarian cancer. *J Gynecol Oncol*. 2019;30(5):e75. 42. Ersoy E, Cao QJ, Otis CN. HER2 protein overexpression and gene amplification in tubo-ovarian high-grade serous carcinomas. *Int J Gynecol Pathol*. 2022;41(4):313-319. 43. Pils D, Pinter A, Reibenwein J, et al. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. *Br J Cancer*. 2007;96(3):485-491. 44. Panek G, Ligaj M. Prognostic significance of HER-2/neu expression in patients at early clinical stages of invasive cervical cancer. *Curr Gynecol Oncol*. 2007;5(4):218-235. 45. Shi H, Shao Y, Lu W, Lu B. An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification. *J Pathol Clin Res*. 2021;7(1):86-95. 46. Itkin B, Garcia A, Straminsky S, et al. Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis. *PLoS One*. 2021;16(9):e0257976. 47. Garrison LP Jr, Babigumira JB, Masquel A, Wang BCM, Lalla D, Brammer M. The lifetime economic burden of inaccurate HER2 testing: estimating the costs of false-positive and false-negative HER2 test results in US patients with early-stage breast cancer. *Value Health*. 2015;18(4):541-546. 48. Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer—an example of personalised medicine in action. *Cancer Treat Rev*. 2013;39(6):592-601. 49. Ben-Assuli O, Sagi D, Leshno M, Ironi A, Ziv A. Improving diagnostic accuracy using EHR in emergency departments: a simulation-based study. *J Biomed Inform*. 2015;55:31-40. 50. McGreevey JD 3rd. Order sets in electronic health records: principles of good practice. *Chest*. 2013;143(1):228-235.